CHFS
NASDAQCHF Solutions, Inc.
News25/Ratings0
Latest news
25 items- PRNuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH GrantEDEN PRAIRIE, Minn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Critically-ill children and babies with kidney failure or who are dependent on artificial kidney support currently do not have enough therapeutic options. Nuwellis (NASDAQ:NUWE) plans to fill this unmet need with the development of a fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. Nuwellis is a medical device company dedicated to transforming care for patients suffering from fluid imbalance. The new device will build on the existing technology of the company's Aquadex SmartFlow® system, and will be funded in part by a $1.7 million grant from the Nati
- PRNuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following
- PRAmerican Medical Association Issues New CPT Code for Nuwellis' Aquadex UltrafiltrationEDEN PRAIRIE, Minn., July 13, 2021 (GLOBE NEWSWIRE) -- In an effort to increase the availability of life-saving ultrafiltration therapy to people experiencing fluid overload, the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code, 0692T for Therapeutic Ultrafiltration. The new CPT code will come into effect on January 1, 2022, at which time providers can utilize the code when using Aquadex® to deliver ultrafiltration to adults and children (20 kg or more). Aquadex is developed and marketed by Nuwellis, Inc. (NASDAQ:NUWE). A specific code for ultrafiltration was granted after a thorough review and validation that the technology met t
- PRNuwellis Announces New Appointments to Leadership TeamEDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex
- PRNationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. CollaborationEDEN PRAIRIE, Minn., June 01, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., has been awarded a three-year national contract with Premier, Inc., effective today. The new Aquapheresis category agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Aquadex SmartFlow®, the gentle fluid management technology developed by Nuwellis. Aquadex® is the first and only therapy currently available in this newly-established Aquapheresis product category. The collaboration provides Nuwellis with the opportunity to expand into many of the thousands of hospitals with which Premier holds
- PRACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart FailureEDEN PRAIRIE, Minn., May 17, 2021 (GLOBE NEWSWIRE) -- Data supporting the effectiveness of Aquadex FlexFlow® system in the treatment of acutely decompensated heart failure (ADHF) patients was presented May 16th at the 2021 American College of Cardiology conference (ACC). The single-center study evaluated 30 ADHF patients in mainstream setting (i.e., step-down unit, not critical care) who were treated with Aquadex therapy. The Aquadex FlexFlow is developed by Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., a company dedicated to changing the lives of people suffering from fluid overload. The study showed 83% of patients treated with Aquadex therapy experienced clinical sympto
- PRNuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company UpdateEDEN PRAIRIE, Minn., May 11, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (previously CHF Solutions, Inc.) announced today its results for the first quarter ended March 31, 2021, which included the following highlights: Completed corporate rebranding from CHF Solutions, Inc. to Nuwellis, Inc. on April 27, 2021Revenue for the first quarter ended March 31, 2021, was $1.9 million, an increase of 18 percent compared to the prior year periodIncreased Aquadex therapy utilization amongst strategic Critical Care accounts; highest levels seen in the past five quartersEnrolled first pediatric patient into clinical registry in April 2021Received strong endorsements f
- PRNuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021EDEN PRAIRIE, Minn., April 29, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), formally CHF Solutions, announces today that its first quarter 2021 financial results will be released on Tuesday, May 11, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com or access the webcast directly at http://ir.nuwellis.com/events. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and usin
- PRCHF Solutions Expands Commercial Focus, Changes Name to NuwellisEDEN PRAIRIE, Minn., April 27, 2021 (GLOBE NEWSWIRE) -- Company names are reflective of the services provided to its customers, and CHF Solutions – a leader and pioneer in the heart failure space – has evolved to serve more than just the chronic heart failure community. The company today announced it is now Nuwellis, Inc. (NASDAQ:NUWE) to reflect its core therapeutic focus areas: pediatric, critical care, and heart failure fluid imbalance. Historically, the company's Aquadex SmartFlow® System was used to remove excess fluid in patients suffering from heart failure, helping to alleviate the burden that fluid overload has on vital organs and subsequently reducing the need for hospital
- SECCHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRCHF Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Two Texas HospitalsEDEN PRAIRIE, Minn., April 23, 2021 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a commitment CHF Solutions (NASDAQ:CHFS) stands by. The company today announced Aquadex SmartFlow® is now available at two new pediatric hospitals in Texas. CHF Solutions is a medical device company dedicated to changing the lives of patients suffering from fluid overload. Pediatric patients suffering from fluid overload require gentle treatment approaches, which makes Aquadex® uniquely beneficial for children. The device is designed to remove small amounts of fluid over time and only requires 35 ml of extracorporeal fluid. This is a key differentiator compared to other fl
- PRCHF Solutions Announces First Patient Enrolled in the ULTRA-Peds RegistryEDEN PRAIRIE, Minn., April 20, 2021 (GLOBE NEWSWIRE) -- More pediatric clinical evidence is essential in understanding the real-world benefits of medical devices in children. CHF Solutions is committed to expanding pediatric-specific data, and today announced Joe DiMaggio Children's Hospital in Hollywood, Florida has enrolled the first patient in the Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds Registry). ULTRA-Peds will collect real-world evidence on the safety, performance and utilization of Aquadex SmartFlow® in fluid overloaded children who weigh 20 kg or more. CHF Solutions is the sponsor of the registry alongside collaborator Acute Kidney Injury Critical Care Research
- INSIDERSEC Form 3 filed by Wotta Paul3 - CHF Solutions, Inc. (0001506492) (Issuer)
- SECSEC Form DEF 14A filed by CHF Solutions, Inc.DEF 14A - CHF Solutions, Inc. (0001506492) (Filer)
- PRThe Portability of Aquadex SmartFlow® from CHF Solutions Could Mean More Critically-Ill Patients Have Access to Life-Saving Ultrafiltration TherapyEDEN PRAIRIE, Minn., April 08, 2021 (GLOBE NEWSWIRE) -- Bringing transportable care directly to patients who are too critically-ill to be moved could be the difference between life and death. New evidence demonstrates that ultrafiltration therapy (aquapheresis) using the Aquadex SmartFlow® system by CHF Solutions may be lifesaving for patients with profound and catastrophic multi-organ failure due to fluid overload, in part due to the device’s flexibility and portability. Aquadex™ gently removes excess fluid from the blood to alleviate burden on key organs such as the kidneys and heart. The case study, “Aquapheresis for Life-threatening Cardio-Respiratory Failure,” is part of an abst
- SECCHF Solutions, Inc. filed SEC Form 8-K: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers8-K - CHF Solutions, Inc. (0001506492) (Filer)
- SECSEC Form 10-K filed by CHF Solutions, Inc.10-K - CHF Solutions, Inc. (0001506492) (Filer)
- 13D/GSEC Form SC 13G filed by CHF Solutions, Inc.SC 13G - CHF Solutions, Inc. (0001506492) (Subject)
- 13D/GSEC Form SC 13G filed by CHF Solutions, Inc.SC 13G - CHF Solutions, Inc. (0001506492) (Subject)
- PRCHF Solutions, Inc. Announces Closing of $20.9 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment OptionEDEN PRAIRIE, Minn., March 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) today announced the closing of its previously announced underwritten public offering of 3,795,816 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $20.9 million, including the full exercise of the underwriters’ over-allotment option to purchase additional shares of the Company’s common stock, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the offering. Lake Street Capital Markets, LLC act
- SECSEC Form 424B5 filed by CHF Solutions, Inc.424B5 - CHF Solutions, Inc. (0001506492) (Filer)
- SECSEC Form 8-K filed by CHF Solutions, Inc.8-K - CHF Solutions, Inc. (0001506492) (Filer)
- PRCHF Solutions, Inc. Announces Pricing of $18.1 Million Underwritten Public Offering of Common StockEDEN PRAIRIE, Minn., March 17, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) today announced the pricing of an underwritten public offering of 3,300,710 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $18.1 million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters an option, exercisable in whole or in part for 45 days, to purchase up to an additional 495,106 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Ladenburg Thalmann & Co. Inc. is acting as sol
- SECSEC Form S-3MEF filed by CHF Solutions, Inc.S-3MEF - CHF Solutions, Inc. (0001506492) (Filer)
- SECSEC Form 424B5 filed by CHF Solutions, Inc.424B5 - CHF Solutions, Inc. (0001506492) (Filer)